Abstract:ABSTRACT Aim: Nomograms are powerful methods for individually predicting prognosis of cancer patients through combining extensive significant prognostic factors. The aim of this study was to develop a nomogram to predict overall survival (OS) of non-metastatic nasopharyngeal carcinoma (NPC) patients who had undergone curative therapy (radiochemotherapy). Methods: We retrospectively collected a consecutive cohort of 1520 NPC patients who received treatment at Cancer Center of Sun Yat-sen University during November 2000 to September 2003. Multivariate stepwise Cox regression analysis was used to identify prognostic factors which were then integrated to establish the nomogram. The predictive accuracy and discriminative ability was measured by concordance index (C-index) and risk group stratification. The nomogram was subjected to bootstrap internal validation as well as external validation with a separate cohort of 464 patients who received intensity modulated radiation therapy (IMRT) in our center. Results: From 16 variables being examined, we identified 7 independent prognostic factors (age, T stage, N stage, body mass index, neutrophil-lymphocyte ratio, serum level of lactate dehydrogenase and alkaline phosphatase). A nomogram was built by incorporating these factors. The calibration curves showed that prediction of 1, 3, and 5-year OS were in good concordance with the actual observation in the bootstrap validation, but were slightly underestimated in the IMRT cohort. The C-index of the nomogram was statistically higher than that of the 7th edition TNM stage for predicting survival (0.68 vs. 0.62, P = 0.01). The stratification into different risk groups allowed significant segregation of survival curves in each TNM stage respectively, which could be also applied to IMRT cohort. Conclusions: We developed and validated a novel nomogram that provided more accurate prediction for OS of non-metastatic NPC patients who had undergone curative therapy, compared with the TNM staging system. In addition, this prognostic model could project to patients who received IMRT. External validation is ongoing. Disclosure: All authors have declared no conflicts of interest.

Development and validation of a nomogram to predicting the efficacy of PD-1/PD-L1 inhibitors in patients with nasopharyngeal carcinoma

Development of Nomograms to Predict Therapeutic Response and Prognosis of Non-Small Cell Lung Cancer Patients Treated with Anti-Pd-1 Antibody

Nomogram Based on Liver Function Test Indicators for Survival Prediction in Nasopharyngeal Carcinoma Patients Receiving PD-1 Inhibitor Therapy

A nomogram based on the SII3 and clinical indicators predicts survival in patients with nasopharyngeal carcinoma treated with PD-1 inhibitors

Development and validation of nomogram based on SIRI for predicting the clinical outcome in patients with nasopharyngeal carcinomas.

Integrating Baseline Nutritional and Inflammatory Parameters with Post-Treatment EBV DNA Level to Predict Outcomes of Patients with De Novo Metastatic Nasopharyngeal Carcinoma Receiving Chemotherapy Combination PD-1 Inhibitor

Development of a prognostic model to identify the metastatic nasopharyngeal carcinoma patients who may benefit from chemotherapy combination PD-1 inhibitor

Development and internal validation of a nomogram based on peripheral blood inflammatory markers for predicting prognosis in nasopharyngeal carcinoma

A nomogram based on nutritional and inflammatory parameters to predict DMFS and identify beneficiaries of adjuvant chemotherapy in IVA-stage nasopharyngeal carcinoma

Dynamic Serum Biomarkers to Predict the Efficacy of PD-1 in Patients with Nasopharyngeal Carcinoma

Development of A Nomogram for Progression-free Survival in Patients with Stage II/T3N0 Nasopharyngeal Carcinoma to Explore Different Treatment Modalities

Prognostic Nomogram For Patients With Nasopharyngeal Carcinoma After Intensity-Modulated Radiotherapy

1022PDEVELOPMENT AND VALIDATION OF A NOMOGRAM FOR PREDICTING OVERALL SURVIVAL OF PATIENTS WITH NON-METASTATIC NASOPHARYNGEAL CARCINOMA AFTER CURATIVE THERAPY

Establishment and validation of two nomograms to predict the benefit of concurrent chemotherapy in stage II-IVa nasopharyngeal carcinoma patients with different risk factors: Analysis based on a large cohort.

Development of Prognostic Nomogram Based on Lipid Metabolic Markers and Lactate Dehydrogenase in Non-Metastatic Nasopharyngeal Carcinoma.

Integration of MRI-Based Radiomics Features, Clinicopathological Characteristics, and Blood Parameters: A Nomogram Model for Predicting Clinical Outcome in Nasopharyngeal Carcinoma

Development and Validation of a Nomogram for Predicting Long-Term Overall Survival in Nasopharyngeal Carcinoma

Development and Validation of a Nomogram for Predicting the Survival of Patients with Non-Metastatic Nasopharyngeal Carcinoma after Curative Treatment

A new prognostic model for predicting outcomes of patients with recurrent or metastatic nasopharyngeal carcinoma receiving subsequent line (≥2 lines) anti-programmed death-1 monotherapy

Clinical observational study on the efficacy of induction chemotherapy sequential concurrent radiotherapy combined with targeted therapy in patients with locally advanced EGFR-positive nasopharyngeal carcinoma: prediction model construction and efficacy testing

An Inflammatory Biomarker‐based Nomogram to Predict Prognosis of Patients with Nasopharyngeal Carcinoma: an Analysis of a Prospective Study